Aceturato de diminazeno e dipropionato de imidocarb no controle de infecção por Trypanosoma evansi em Rattus norvegicus infectados experimentalmente

Silva, Aleksandro S. Da; Tochetto, Camila; Zanette, Régis A.; Pierezan, Felipe; Rissi, Daniel R.; Santúrio, Jânio Morais; Monteiro, Sílvia González

doi:10.1590/s0103-84782008000500025

Cited by 27 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a single dose is not effective for horses, mules and dogs (Tuntasuvan et al 2003;Colpo et al 2005), resulting in lack of efficacy of these drugs (Tuntasuvan et al 2003;Da Silva et al 2008). In addition, the drugs used to treat T. evansi are considered hepatotoxic and nephrotoxic (Spinosa et al 1999), and their prolonged use can cause worsening of the disease.…”

Section: Introductionmentioning

confidence: 99%

Cordycepin (3′-deoxyadenosine) pentostatin (deoxycoformycin) combination treatment of mice experimentally infected withTrypanosoma evansi

et al. 2013

View full text Add to dashboard Cite

The aim of this study was to evaluate the anti-trypanosomal effect of treatment with 3'-deoxyadenosine (cordycepin) combined with deoxycoformycin (pentostatin: inhibitor of the enzyme adenosine deaminase) in vitro by using mice experimentally infected with Trypanosoma evansi. In vitro, a dose-dependent trypanocidal effect of cordycepin was observed against the parasite. In the in vivo trials, the two drugs were used individually and in combination of different doses. The drugs when used individually had no curative effect on infected mice. However, the combination of cordycepin (2 mg kg-1) and pentostatin (2 mg kg-1) was 100% effective in the T. evansi-infected groups. There was an increase in levels of some biochemical parameters, especially on liver enzymes, which were accompanied by histological lesions in the liver and kidneys. Based on these results we conclude that treatment using the combination of 3'-deoxyadenosine with deoxycoformycin has a curative effect on mice infected with T. evansi. However, the therapeutic protocol tested led to liver and kidney damage, manifested by hepatotoxicity and nephrotoxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Cordycepin (3′-deoxyadenosine) pentostatin (deoxycoformycin) combination treatment of mice experimentally infected withTrypanosoma evansi

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Our research group has investigated in recent years alternative treatments for T. evansi infection because chemotherapy with diminazene aceturate and suramim used in the treatment of trypanosomosis has proved ineffective in many cases (TUNTASUVAN et al, 2003;SILVA et al, 2008b;SILVA et al, 2010). Studies have demonstrated that these drugs have limited effectiveness because they do not cross the blood-brain barrier, thereby creating a potential refuge for trypanosomes during the systemic phase of drug action (JENNINGS et al, 1977;SPINOSA et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

Trypanocidal activity of human plasma on Trypanosoma evansi in mice

Silva

Duck

Fanfa

et al. 2012

Rev. Bras. Parasitol. Vet.

Self Cite

View full text Add to dashboard Cite

This study aimed to test an alternative protocol with human plasma to control Trypanosoma evansi infection in mice. Plasma from an apparently 27-year-old healthy male, blood type A+, was used in the study. A concentration of 100 mg.dL-1 apolipoprotein L1 (APOL1) was detected in the plasma. Forty mice were divided into four groups with 10 animals each. Group A comprised uninfected animals. Mice from groups B, C and D were inoculated with a T. evansi isolate. Group B was used as a positive control. At three days post-infection (DPI), the mice were administered intraperitoneally with human plasma. A single dose of 0.2 mL plasma was given to those in group C. The mice from group D were administered five doses of 0.2 mL plasma with a 24 hours interval between the doses. Group B showed high increasing parasitemia that led to their death within 5 DPI. Both treatments eliminated parasites from the blood and increased the longevity of animals. An efficacy of 50 (group C) and 80% (group D) of human plasma trypanocidal activity was found using PCR. This therapeutic success was likely achieved in the group D due to their higher levels of APOL1 compared with group C.

show abstract

“…A research group has investigated in recent years alternative treatments for T. evansi infection because chemotherapy with diminazene aceturate and suramim used in the treatment of trypanosomosis has proved ineffective in many cases [24,41,42]. Studies have demonstrated that these drugs have limited effectiveness because they do not cross the blood-brain barrier, thereby creating a potential refuge for trypanosomes during the systemic phase of drug action [43,44].…”

Section: Apol1 : a Future Hope For Treatment Of Trypanosoma Evansi Inmentioning

confidence: 99%

Is Atypical Human Trypanosomosis an Emering Threat to Human Society? : A Debatable one Health Issue to Public Health Experts and Parasitologists

Parashar¹,

Singla²,

Kaur³

2016

Int J Vet Sci Res

View full text Add to dashboard Cite

Trypanosomosis is caused by different species of unicellular eukaryotic haemofl agellate Trypanosoma. Though human infection by animal species of trypanosomes is "not possible" as these species fails to infect humans due to innate immunity of the host due to presence of trypanolytic factor in human serum, however, across the world 20 patients with atypical human trypanosomosis are documented, eight of which are confi rmed between 1974 and 2014 due to improved molecular diagnostic assays. However, the numbers of cases are atypical human trypanosomosis caused by animal trypanosomes might be underestimated. Ten atypical cases of human trypanosomosis have so far been reported form Indian subcontinent. Out of these, nine cases were from India and one from Sri Lanka. Three cases of human T. evansi have been reported from the Indian subcontinent (one from Sri Lanka and two from India) during the last decade. Apart from these three cases, at least six more atypical human cases of trypanosomosis caused by rat trypanosome, T. lewisi have been reported. Two casualties due to non-tsetse transmitted trypanosomosis (NTTT) were also reported from India. High prevalence of these two animal trypanosomes in India is now a matter of concern for public health specialists. These raise it as an alarming situation of emerging new zoonotic disease and debatable one health issue to public health experts and parasitologist. There is a need to investigate disease with modern diagnostics by epidemiological based surveys in the fi eld to know the exact situation of the disease. Veterinarian can play very crucial role in diagnosis and control of disease, also by educate and re-educate people about the transmission, prevention and control of disease.

show abstract

Aceturato de diminazeno e dipropionato de imidocarb no controle de infecção por Trypanosoma evansi em Rattus norvegicus infectados experimentalmente

Cited by 27 publications

References 19 publications

Cordycepin (3′-deoxyadenosine) pentostatin (deoxycoformycin) combination treatment of mice experimentally infected withTrypanosoma evansi

Cordycepin (3′-deoxyadenosine) pentostatin (deoxycoformycin) combination treatment of mice experimentally infected withTrypanosoma evansi

Trypanocidal activity of human plasma on Trypanosoma evansi in mice

Is Atypical Human Trypanosomosis an Emering Threat to Human Society? : A Debatable one Health Issue to Public Health Experts and Parasitologists

Contact Info

Product

Resources

About